PLUS1
0.483
-0.007 (-1.43%)
-0.007 (-1.43%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Onconova Therapeutics Inc | ONTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.007 | -1.43% | 0.483 | 0.4641 | 0.518 | 0.482 | 0.49 | 15:26:36 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.483 | 0.4889 | 0.006 | 1.23% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,236 | 9,814,580 | $ 0.4955876 | $ 4,863,984 | 21,993,791 | 0.1027 - 5.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:26:43 | 2,275 | $ 0.483 | USD |
Onconova Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 67.98M | 138.73M | $ -20.57M | -7.93 | - | 137.22M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Onconova Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/19/2020 | 06:00 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 2/18/2020 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics Announces Participation in Two.. |
| 2/14/2020 | 17:24 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/14/2020 | 17:09 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/14/2020 | 14:05 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/10/2020 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics to Present Update at Noble Capital.. |
| 2/04/2020 | 08:00 | GlobeNewswire Inc. | Onconova Therapeutics to Present Update at the 2020 BIO CEO.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.49 | 0.59 | 0.4523 | 0.5265182 | 14,366,297 | -0.007 | -1.43% |
| 1 Month | 0.381 | 0.749 | 0.293 | 0.5008115 | 26,037,394 | 0.102 | 26.77% |
| 3 Months | 0.34 | 0.749 | 0.25 | 0.4348491 | 22,813,741 | 0.143 | 42.06% |
| 6 Months | 2.34 | 2.84 | 0.1027 | 0.4084232 | 12,629,130 | -1.86 | -79.36% |
| 1 Year | 3.75 | 5.25 | 0.1027 | 0.4209876 | 6,489,196 | -3.27 | -87.12% |
| 3 Years | 43.35 | 58.20 | 0.1027 | 2.05 | 2,556,326 | -42.87 | -98.89% |
| 5 Years | 33.75 | 122.55 | 0.1027 | 3.17 | 1,597,571 | -33.27 | -98.57% |
Onconova Therapeutics Description
| Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways. |
